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ABSTRACT
Rationale A previous analysis found significantly higher 
lung function in the US paediatric cystic fibrosis (CF) 
population compared with the UK with this difference 
apparently decreasing in adolescence and adulthood. 
However, the cross- sectional nature of the study makes it 
hard to interpret these results.
Objectives To compare longitudinal trajectories of lung 
function in children with CF between the USA and UK 
and to explore reasons for any differences.
Methods We used mixed effects regression analysis to 
model lung function trajectories in the study populations. 
Using descriptive statistics, we compared early growth 
and nutrition (height, weight, body mass index), 
infections (Pseudomonas aeruginosa, Staphylococcus 
aureus) and treatments (rhDnase, hypertonic saline, 
inhaled antibiotics).
Results We included 9463 children from the USA and 
3055 children from the UK with homozygous F508del 
genotype. Lung function was higher in the USA than in 
the UK when first measured at age six and remained 
higher throughout childhood. We did not find important 
differences in early growth and nutrition, or P.aeruginosa 
infection. Prescription of rhDNase and hypertonic saline 
was more common in the USA. Inhaled antibiotics 
were prescribed at similar levels in both countries, but 
Tobramycin was prescribed more in the USA and colistin 
in the UK. S. aureus infection was more common in the 
USA than the UK.
Conclusions Children with CF and homozygous 
F508del genotype in the USA had better lung function 
than UK children. These differences do not appear 
to be explained by early growth or nutrition, but 
differences in the use of early treatments need further 
investigation.
INTRODUCTION
Cystic fibrosis (CF) is a serious, multiorgan inher-
ited disease characterised by pulmonary infections 
and progressively declining lung function. Most 
people with CF die prematurely from their disease 
through respiratory failure.1 2 In the 1960s, median 
survival in the UK was estimated to be below 10 
years of age.3 Over the past decades, outcomes 
have improved due to multidisciplinary care, nutri-
tional support and new treatments, such that half 
of the babies born with CF in the UK and the USA 
today can be expected to live at least in to their late 
forties.2 4–6
Previous international comparisons of outcomes 
in people with CF have highlighted the impact 
of different healthcare practices and approaches 
to treatment, and have contributed to improve-
ments in care for people with CF. For example, 
comparisons of nutritional, pulmonary and survival 
outcomes between the USA and Canadian CF popu-
lations provided evidence for high- fat, high- calorie 
diets for people with CF.7 8
A previous cross- sectional study comparing the 
2010 US and UK CF populations suggested better 
lung function in children in the USA compared 
with those in the UK. After adjustment for a set of 
potential demographic and clinical confounders, 
the authors estimated a difference in percent of 
predicted forced expiratory volume in 1 s (%FEV1) 
of 7.62 percentage points (95% CI 6.24 to 9.00) 
between children in the USA and UK under the 
age of 12. This difference seemed to be smaller in 
adolescence and disappeared by age 30.9 However, 
due to the cross- sectional nature of the study, the 
age trends demonstrated could not be interpreted 
as average trends for individuals over time. The 
narrowing of the US- UK gap with increasing age 
was therefore difficult to interpret, conflating 
potentially different rates in lung function decline 
Key messages
What is the key question?
 ► Was there a difference in the longitudinal 
trajectories of lung function in children with 
cystic fibrosis between the USA and UK during 
2003–2014?
What is the bottom line?
 ► Children with cystic fibrosis and homozygous 
F508del genotype in the UK had persistently 
worse lung function than those in the USA.
Why read on?
 ► This finding does not appear to be explained 
by differences in casemix or early growth or 
nutrition, but there are differences in the use 
of early treatments between the two countries 
which will need further investigation.
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between populations with cohort effects and survivor bias later 
in adulthood. The aim of this study was, therefore, to compare 
lung function trajectories, that is, lung function at age 6 years 
and rates of lung function decline, between the US and UK popu-
lations. Secondary aims were to explore potential reasons for 
any differences demonstrated. To ensure comparability of popu-
lations, we restricted our analysis to the paediatric populations 
to reduce the impact of survivor bias, and to people who were 
homozygous F508del—the most common CF genotype—to 
reduce differences in case- mix.
METHODS
Study design
We carried out retrospective longitudinal analyses of lung func-
tion in comparable cohorts of children with CF aged ≥6 to<18 
years and with homozygous F508del genotype captured in the 
US Cystic Fibrosis Foundation Patient Registry (CFFPR) and UK 
Cystic Fibrosis Registry.
Data sources
We used the US CFFPR and the UK CF Registry. The current 
CFFPR includes data from 1986 onwards on over 50 000 people 
with CF and is estimated to capture about 84% of the current 
US CF population. Since 2003, CF care centres have been 
encouraged to enter information from all clinical encounters 
at CF Foundation Care Centre Network facilities.10 Current 
CFF guidelines are for people with CF to be seen quarterly for 
routine care.11
In the UK, it is recommended that care teams submit annual 
encounter data to the Registry from a clinic visit approximately 
12 months after the previous entry and when the patient is clini-
cally stable. Records date back to the 1990s and are estimated to 
capture approximately 99% of the current CF population.12 See 
online supplemental material section 1 for more details.
Setting and participants
We included children aged ≥6 to <18 with homozygous F508del 
genotype with data recorded in the CFFPR or UK CF Registry 
between January 2003 and December 2014 and with at least one 
lung function measurement in that time period. Restricting the 
analysis to children with CF who were homozygous for F508del 
reduced the differences in casemix between the two countries. 
The dates were chosen to ensure comparability between popula-
tions as it preceded licensing of Orkambi (lumacaftor/ivacaftor) 
in the USA. For individuals who had a transplant, observations 
were censored at transplant.
We excluded individuals who did not have complete data on 
sex, year of birth and age at diagnosis.
Outcomes and covariates
Our main outcome of interest was lung function measured by 
percent of predicted %FEV1 based on GLI reference equations
13 
and the rate of lung function decline.
Secondary outcomes were time- varying indicators of growth 
and nutrition (height, weight, body mass index (BMI); raw 
values and z- scores using the Centers for Disease Control and 
Prevention (CDC) reference populations in both countries 
and additionally UK- WHO reference population in the UK), 
prescribed chronic medications (rhDNase, hypertonic saline), 
common inhaled antibiotics (Tobramycin, Colistin, Aztreonam) 
and common infections (Pseudomonas aeruginosa, Staphylo-
coccus aureus) between birth and age 18 for the study popula-
tion. More information on secondary outcomes and when they 
began collection can be found in online supplemental material 
section 1 table 1.
To adjust for remaining potential differences in case- mix, 
we included the following baseline covariates in the models 
used: sex (binary: male/female; reference level: female), year 
of birth (continuous, centred at 1997) and age at diagnosis 
(continuous).
Statistical analysis
Using all the collected data on our study population from age 
6 up to (excluding) age 18 (encounter data in the USA and 
annual review data in the UK), we developed models for the 
longitudinal trajectories of lung function to compare estimated 
population- level mean lung function and population- level mean 
lung function decline by age between the US and UK paediatric 
populations.
We fitted a series of models of different complexity to the US 
and UK study populations. We fitted models using linear,14 15 
quadratic and cubic polynomials of age, and models including 
flexible functions of age16 17 using natural cubic splines with one 
knot at age 12, two knots at ages 8 and 14, 5 knots with one knot 
every 2 years (8, 10, 12, 14 and 16 years) and 11 knots – one 
every year. All models included sex, year of birth and age at diag-
nosis as covariates; year of birth and age at diagnosis entered the 
models linearly. We did not consider any interactions between 
functions of age and the covariates (for exploratory plots, see 
online supplemental material section 2).
To appropriately capture the correlation between repeated 
measurements within an individual over time, we initially 
included random intercepts in the models and then added: 
(1) random slope (only in the model with a linear function of 
age), (2) random slope and exponential correlation function 
(only in the model with a linear function of age), (3) expo-
nential correlation function and (4) linear correlation func-
tion. Within each country all the model fits were compared 
using the log- likelihood, Akaike information criterion (AIC) 
and Bayesian information criterion (BIC); the best fitting 
models are those with the highest log- likelihood, lowest AIC 
and lowest BIC. For more details, see online supplemental 
material section 3.
To explore reasons for any differences in lung function 
trajectories we compared indicators of growth and nutrition, 
treatments, and infections cross- sectionally from birth to age 
18 between the two study populations. This included records 
collected prior to 2003 on individuals in the study popula-
tion. Observations remained censored at lung transplant. We 
summarised height, weight and BMI by their median, 25th 
and 75th percentile at each year of age for all individuals in 
the study population for whom data were available at that 
age. For treatments and infections we presented the propor-
tion of individuals with at least one record of receiving the 
treatments/having the infections before age 6, before age 12 
and before age 18 years; as well as the median, 25th and 
75th percentile, minimum and maximum of the age at first 
recorded treatment/infection.
We stratified these comparisons by year of birth (before and 
after 1997) as post 1997 data will be more complete with regard 
to treatments and infections and may give a better representation 
of healthcare practices.
We used R packages nlme18 and splines19 for data analysis 
and ggplot220 and the dns() function from the JMbayes21 
package for visualisations; online supplemental material used 
knitr.22 23
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To assess the generalisability of our results to more recent paedi-
atric CF populations, we repeated our analysis using the best 
fitting models applied to the recent cohort born after 1997.
RESULTS
Study populations
There were 9463 and 3055 individuals in the US and UK study 
population, respectively (see online supplemental material 
section 4 for the derivation of the study populations). In the 
USA, individuals had a median of 24 lung function measure-
ments, with a median of 4 (IQR: 3–6) measures per individual 
per year (table 1). In the UK, each individual had a recorded 
review measurement approximately once a year, with a median 
of 4 lung function measurements during the study period. The 
average lung function for those observed at age 6 was 93 (SD: 
17.7) in the USA and 88.2 (SD: 16.9) %FEV1 in the UK. The 
populations were generally comparable with regard to their 
demographic characteristics (table 1, online supplemental mate-
rial section 5).
Estimated lung function and lung function decline
In both countries, the estimated population- level mean lung 
function between ages 6 and 18 and the covariate effects were 
very similar across all the different models (online supplemental 
material section 6). The best fitting model for lung function in 
both countries was the model with a linear term for age with 
random intercept, random slope and exponential correlation 
function. In the USA, the model including age using a spline 
with five knots, random intercept and exponential correlation 
function gave only a marginally worse fit, therefore, we report 
results for both models.
Population mean lung function was higher in the US study 
population throughout childhood (figure 1). Based on our model 
that included a linear function of age, lung function declined at 
a faster rate in the UK than in the US population (−1.61 per 
year (95% CI: −1.72 to −1.50) in the UK compared with −1.41 
(95% CI: −1.47 to –1.36) in the USA); children in the UK lost 
on average an additional 0.20 percentage points in %FEV1 per 
year (95% CI 0.08 to 0.32) compared with the USA. Based on 
the model that included age using a spline with five knots there 
was an indication of a faster rate of decline in the UK at almost 
all ages but the evidence was not clear (figure 1, online supple-
mental material section 8).
Based on the model with a linear term for age and covariate 
reference levels (female, born in 1997, diagnosed at birth) the 
estimated difference between the USA and UK populations at 
ages 6, 12 and 17 was 3.60 (95% CI 2.40 to 4.80), 4.80 (95% 
CI 3.38 to 6.22) and 5.80 (95% CI 3.98, 7.62) % FEV1, respec-
tively. Based on the model including age using a spline model 
with five knots, the difference between the two countries was 
3.89 (95% CI 2.00, 5.77), 4.78 (95% CI 3.10 to 6.47) and 5.69 
(95% CI 3.97 to 7.41)% FEV1 at ages 6, 12 and 17, respectively. 
The US- UK gap was estimated to increase over calendar time by 
0.13% predicted per year of birth (95% CI 0.003 to 0.25) based 
on the model with a linear term for age, and 0.12% predicted 
per year (95% CI −0.01 to 0.25) based on the model including 
age using a spline with five knots (table 2). In the UK, males 
had on average 2.50 percentage points (95% CI 1.32 to 3.67) 
higher %FEV1 than females, whereas in the USA, the difference 
was 1.42 percentage points (95% CI 0.70 to 2.14) (based on the 
model with a linear term for age; results were similar for the 
model that included age using a spline with five knots). The 
difference between the US and UK populations may therefore 
be less for males than females (see online supplemental material 
section 7 for estimated differences between the US and UK for 
selected sets of covariate values).
Indicators of growth and nutrition, treatments and infections
Children in the US study population were on average lighter and 
shorter than children in the UK population during childhood 
and into adolescence (figure 2, online supplemental material 
section 9).
Rates of infection with P. aeruginosa were similar in both 
countries but methicillin sensitive and methicillin resistant S. 
aureus infections were more common in the US (online supple-
mental material section 11).
A larger proportion of the study population was treated with 
rhDNase and hypertonic saline in the USA compared with the UK. 
In the post 1997 birth cohort, 73% were treated with rhDNase 
before age 6 in the USA and 96% before age 18 compared with 
20% and 86%, respectively, in the UK (online supplemental 
material section 10). Hypertonic saline was prescribed for 76% 
of the study population before age 18 in the post 1997 birth 
cohort in the USA vs 50% in the UK (online supplemental mate-
rial section 10). Inhaled antibiotics were prescribed at slightly 
higher levels before age 6 in the USA but prescribed at similar 
levels at later ages (online supplemental material section 10). 
However, there was a big difference in the inhaled antibiotic 
of choice between the two countries. Tobramycin was the most 
Table 1 Details of the datasets and study populations in the USA 
and UK, respectively
US data UK data
Sample size 9463 3055
No of FEV1 measures per 
person
(median (IQR), (full range))
24 (11–40), (1–199) 4 (2–7), (1–17)
No of individuals with one 
FEV1 measure (%)
251 (2.7) 398 (13.0)
No of FEV1 measures per 
person per year (median (IQR))
4 (3–6) 1 (1–1)
Time in years between first 
and last FEV1 measurement 
included in the study per 
person (median (IQR))*
5.5 (2.7–8.4) 4.9 (2.2–7.5)
Informative drop- out during 
study period (%)
    
Lung transplants 142 (1.5) 27 (0.9)
Deaths 263 (2.8) 70 (2.3)
Sex (%)     
Female 4625 (48.9) 1457 (47.7)
Male 4838 (51.1) 1598 (52.3)
Year of birth (median) (IQR) 1996 (1991–2002) 1996 (1991–2002)
Race (%)     
Non- Caucasian 384 (4.1) 71 (2.3)
Caucasian 9083 (95.9) 2984 (97.7)
Age at diagnosis in years 
(median (IQR))
0.3 (0.0–1.2) 0.2 (0.0–1.0)
Diagnosis by newborn 
screening (%)
1079 (11.4) 501 (16.3)
%FEV1 at age 6 (mean (SD)) 92.96 (17.7) 88.17 (16.9)
*Excluding individuals with only one FEV1 measurement.
FEV1, forced expiratory volume in 1 s.
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prescribed inhaled antibiotic in the USA, whereas Colistin was 
prescribed most in the UK (online supplemental material section 
10).
Robustness test
In both countries lung function decline was less steep in the 
population born after 1997 compared with the whole study 
population. The estimated gap in absolute level of lung function 
was comparable to the estimates derived from the whole popula-
tion (online supplemental material section 12).
DISCUSSION
We assessed longitudinal lung function trajectories in compa-
rable populations of children in the USA and UK using data from 
national registries and found that lung function was better in US 
children over the entire age range from 6 up to age 18 years. For 
example, based on the best fitting longitudinal model, females 
in the USA were estimated to have approximately 3.60 (95% CI 
2.40 to 4.80) and 5.80 (95% CI 3.88 to 7.62) percentage points 
higher %FEV1 than females in the UK at age 6 and 17, respec-
tively. The gap was slightly smaller for males. Children in the 
USA with CF may have a slower rate of decline in lung function 
compared with UK children, but the strength of evidence for 
this was sensitive to modelling choices and was less clear in more 
recent cohorts born after 1997.
Strengths and limitations
A major strength of this study is the use of high quality, longitu-
dinal data with broad national coverage in each country and the 
application of statistical methods suitable for longitudinal data 
analysis which enabled us to compare population level mean 
lung function trajectories across childhood. We fitted a range 
of models to reduce the possibility that estimated differences in 
lung function were due to suboptimal model fit in the popula-
tions. Our main results were consistent across models.
A further strength is the reduction of differences in case- mix 
between the two populations through the restriction to the 
F508del homozygous population and the adjustment for 
important covariates. We also reduced the influence of survivor 
bias by only considering the paediatric populations. However, 
this does mean that our results may not be generalisable to the 
whole CF population and further studies are needed to under-
stand whether the differences we found also exist for different 
genotypes.
The previous study by Goss et al9 accounted for differences 
in data collection methods between registries by merging the US 
Figure 1 Estimated population- level mean lung function (panels A, C) and lung function decline (panels B, D) in the UK and US study populations 
for reference covariate values (female, born in 1997, diagnosed at birth). The top row (A, B) shows results based on the model that included a linear 
term for age with random intercept and slope and exponential correlation function; the bottom row (C, D) shows results based on the model that 
included age using a spline with five knots with random intercept and exponential correlation function. FEV, forced expiratory volume in 1 s.
Table 2 Estimated covariate effects (95% CIs) based on the model that included a linear term for age with random intercept, random slope and 
exponential correlation function and the model that included age using a spline with five knots, random intercept and exponential correlation 
function
US UK
Linear function Spline Linear function Spline
Sex=male 1.42 (0.70, 2.14) 1.80 (1.04, 2.55) 2.5 (1.33, 3.7) 2.71 (1.49, 3.93)
Age at diagnosis 0.59 (0.43, 0.74) 0.57 (0.42, 0.72) 0.62 (0.30, 0.95) 0.6 (0.28, 0.92)
Year of birth 0.37 (0.30, 0.43) 0.42 (0.35, 0.48) 0.24 (0.13, 0.35) 0.3 (0.19, 0.41)
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and UK datasets into a single data set and matching a single US 
clinic visit to a UK annual visit based on month of calendar year. 
In this study we did not try to harmonise the datasets but rather 
used identical inclusion/exclusion criteria and analysis methods. 
By including all available data points, we can more precisely 
estimate trends in lung function and rates of decline, but this 
may lead to bias due to seasonality or time between clinic visits 
(online supplemental material section 1). However, we do not 
expect this to have a major impact on our results as seasonality 
has been shown to have a negligible effect on lung function.15 24 
The difference in the number of data points between the two 
populations is also unlikely to have significantly impacted our 
results based on preliminary findings from a parallel investiga-
tion of different analysis strategies applied to the US CFFPR. 
The potential impacts of these strategies on estimating lung func-
tion decline have been reported in abstract form from a Cystic 
Fibrosis Foundation workgroup.25 The findings show that lung 
function trajectory estimates were similar if using all available 
encounter- level %FEV1 data, median quarterly data or median 
annual data. It has been noted that in the UK CF population, 
the average best measured %FEV1 per year is significantly higher 
(approximately 4 percentage points) than the annual review 
%FEV1 that we used in this study.
2 26 Best FEV1 has only been 
collected in the UK CF Registry since 2012 and therefore we 
could not conduct a full comparison of this measure between the 
two countries. However, a cross- sectional description of annual 
vs best %FEV1 in the UK and average- per- year vs best %FEV1 
in the USA, showed similar differences in the two countries and 
indicated that an analysis using best %FEV1 would likely return 
similar results to our findings (see online supplemental material 
section 13).
Although we adjusted for a number of baseline covariates, 
a limitation remains the potential difference in casemix, espe-
cially due to socioeconomic factors. These have been shown to 
impact outcomes in CF14 27 28 but due to differences in measuring 
socioeconomic status between countries and differences in data 
collection between registries, it was not possible to adjust for 
these. It has previously been suggested that the US CFFPR may 
not capture the full spectrum of socioeconomic conditions as the 
UK CF Registry does. A sensitivity analysis of this assumption in 
relation to the study by Goss et al, however did not alter their 
results significantly and is therefore not likely to have a major 
impact on our findings.29 A related open question is whether 
individuals not captured in the registries differ significantly from 
those who are. If this is the case, then any results from anal-
yses of the registry population may not be generalisable to the 
population as a whole. Therefore, when interpreting the findings 
from our study, we need to be mindful that about 16% of the US 
CF population is not captured by the CFFPR and in the UK it is 
only since 2012 that 99% have been captured.
A further limitation is the generalisability of these results to the 
CF population in the era of new cystic fibrosis transmembrane 
conductance regulator (CFTR) modulators. In future studies, 
it will be important to assess whether the observed differences 
have widened with the earlier introduction of Orkambi (luma-
cavtor/ivacavtor) in the USA compared with the UK and whether 
we can expect the difference to decrease in the next generation 
when both countries will have access to CFTR modulators, 
including the triple combination therapy, for almost the whole 
population. However, the fast- paced development and the varia-
tion in introduction and eligibility criteria for CFTR modulator 
therapies across different countries pose additional difficulties 
for conducting cross- country comparison analyses of registry 
data.
Comparison with previous studies
Our overarching finding, that the paediatric homozygous 
F508del population in the USA had higher lung function than 
this population in the UK, corroborates the results from the 
cross- sectional study by Goss et al. However, the longitudinal 
nature of our study enabled us to compare the population- level 
Figure 2 Cross- sectional summary measures of weight, height and BMI z- scores of the study population based on the CDC reference population in 
the US and the UK. The dots show the median and the lines the IQR. BMI, body mass index.
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mean lung function trajectories throughout childhood. We 
showed that the gap between the two populations was sustained 
and may even be increasing during childhood and adolescence. 
These findings are in contrast to Goss et al who had previously 
found that cross- sectionally the gap in lung function between the 
USA and UK appeared to be decreasing in adolescence and disap-
peared at age 30. Their findings are likely due to cohort effects 
and could be explained by our result that the gap between the 
two countries may be widening with calendar time.
Implications for clinical practice
The sustained gap in lung function between the USA and UK 
which may be increasing with age and calendar time is a major 
concern for the UK CF community. As suboptimal nutritional 
status early in life is associated with lower pulmonary function,30 
we compared anthropomorphic measures between the two 
study populations. Children in our UK study population had on 
average better early nutritional status than children in the US 
study population. If anything, this would portend, if all other 
things were equal, that lung function in the UK would be better 
than in the USA. In other words, the factors contributing to the 
difference in lung function between the two populations may be 
responsible for an even greater difference than just the difference 
reported in our study.
Additional factors such as differential use of medications 
between the countries may impact lung function.31 32 We found 
big differences in the proportion of children receiving rhDNase 
and hypertonic saline with much more aggressive treatment at 
younger ages in the USA compared with the UK. In the pivotal 
study, once daily rhDNase reduced pulmonary exacerbations 
by 28% and improved FEV1 by 5.8% compared with placebo
32 
but a recent study in the UK found that rhDNase may only 
improve lung function in individuals with reduced FEV1 at base-
line.33 In both studies, however, children under 5 years of age 
were excluded and there remains a paucity of data on the use 
of rhDNase in preschool children. Although overall levels of 
prescribed inhaled antibiotics were similar between the coun-
tries, US children were almost entirely treated with Tobramycin. 
Whereas in the UK, colistin was used almost exclusively, especially 
in children under the age of 6. These results raise the question 
whether the earlier prescription of mucoactive agents in the USA 
led to improved lung function at age 6, or whether differences 
between the US and UK in early antibiotic use, both nebulised 
and oral,34 may have an impact on lung function. Further work 
will be needed to investigate this and other potential reasons for 
the observed differences. This will include investigating whether 
there are differences in lung function between the healthy popu-
lations in the USA and the UK. We will also need to understand 
the generalisability of these findings to the whole CF population 
and the implications for long term outcomes including survival 
or time to lung transplant.
CONCLUSION
Using patient registry data to conduct international comparisons 
of health among people with CF is challenging due to varia-
tion in data collection methods but may highlight differences 
in healthcare and health outcomes between countries. In our 
comparative longitudinal analysis of children with CF, we found 
significant differences in lung function between the USA and UK. 
Children in the USA had higher lung function at age six which 
was sustained throughout childhood and adolescence. The rate 
of decline in lung function with age may also be slower in the 
USA. Further work will need to investigate possible reasons for 
the gap in lung function between the USA and the UK at age 6 
including a more detailed analysis of treatment patterns.
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